# EDGAR Filing Document

**Accession Number:** 0001574565
**File Stem:** 0001178913-26-002773
**Filing Date:** 2026-5
**Character Count:** 3566
**Document Hash:** d3c56e7e2f7a1aefb67710d799028fad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002773.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001178913-26-002773

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260518

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evogene Ltd.
- **CENTRAL INDEX KEY:** 0001574565
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36187
- **FILM NUMBER:** 26993006

**BUSINESS ADDRESS:**
- **STREET 1:** 13 GAD FEINSTEIN STREET
- **STREET 2:** PARK REHOVOT
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7638517
- **BUSINESS PHONE:** 97289311900

**MAIL ADDRESS:**
- **STREET 1:** 13 GAD FEINSTEIN STREET
- **STREET 2:** PARK REHOVOT
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7638517

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2026**

Commission File Number: **001-36187**

**EVOGENE LTD.**

&nbsp;&nbsp;&nbsp;&nbsp;(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel** 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**CONTENTS**

On May 18, 2026, Evogene Ltd. ("**Evogene**") announced that its subsidiary Ag Plenus Ltd. ("**AgPlenus**") and Bayer Ag ("**Bayer**") have decided to discontinue their herbicide development project following determination that the target protein did not meet the required product criteria. The termination will enter into effect as of May 18, 2026. Under the terms of the termination, all assets licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus.

The content of this Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. <u>[333-277565](https://www.sec.gov/Archives/edgar/data/1574565/000117891324000782/zk2431068.htm)</u>) and on Form S-8 8 (SEC File Nos. [333-193788](https://www.sec.gov/Archives/edgar/data/1574565/000117891314000421/zk1414344.htm), [333-201443](https://www.sec.gov/Archives/edgar/data/1574565/000117891315000075/zk1516040.htm), [333-203856](https://www.sec.gov/Archives/edgar/data/1574565/000117891315001446/zk1516687.htm), [333-259215](https://www.sec.gov/Archives/edgar/data/1574565/000117891321002873/zk2126521.htm), and [333-286197](https://www.sec.gov/Archives/edgar/data/1574565/000117891325001098/zk2532918.htm)) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| <br>Date: May 18, 2026 | <u>EVOGENE LTD.</u><br> (Registrant)<br>By: <u>/s/ Ofer Haviv</u><br> Ofer Haviv<br> Chief Executive Officer |

---